Cardiotoxicity of Anticancer Drugs

An analysis of the literature for 2022 was carried out in order to study the latest data on the cardiotoxicity of antitumor drugs. The abundance of data on the pathogenesis of cardiotoxicity of even a single chemotherapeutic agent indicates the multifactorial effect and the characteristics of the individual sensitivity of each patient to a particular drug. Due to the multifactorial nature of the pathogenesis of cardiotoxicity, the clinical manifestations of this complication are also numerous. It should be taken into account that oncological patients could have suffered from various cardiovascular diseases even before tumor development, and that cancer progression even without therapeutic intervention, or before it, can cause cardiac side effects. To identify such processes, it is necessary to monitor cardio-oncological patients in dynamics. When conducting conservative cancer treatment and in the event of the development of side effects, the complete cancellation of treatment is impossible, as it is necessary to continue the therapy, as well as repeat its courses, often throughout the patient's life. In this regard, methods are needed to reduce the severity of the cardiotoxic effect, as well as suppress the adverse effects of anticancer drugs on the myocardium, and the search and development of effective methods for the prevention and treatment of cardiotoxicity of chemotherapy drugs are still relevant. Timely detection, and hence, prevention, as well as reduction of the degree of damaging effects of the beginning cardiotoxic effect when using cancer chemotherapy agents is possible only with close cooperation between oncologists and cardiologists.